BR112014019277A8 - Populações de células-tronco estromais, tecidos, métodos de isolamento de células-tronco estromais, método de obtenção de tecido, ensaio e método para condução de ensaio e composição farmacêutica - Google Patents
Populações de células-tronco estromais, tecidos, métodos de isolamento de células-tronco estromais, método de obtenção de tecido, ensaio e método para condução de ensaio e composição farmacêuticaInfo
- Publication number
- BR112014019277A8 BR112014019277A8 BR112014019277A BR112014019277A BR112014019277A8 BR 112014019277 A8 BR112014019277 A8 BR 112014019277A8 BR 112014019277 A BR112014019277 A BR 112014019277A BR 112014019277 A BR112014019277 A BR 112014019277A BR 112014019277 A8 BR112014019277 A8 BR 112014019277A8
- Authority
- BR
- Brazil
- Prior art keywords
- stromal stem
- assay
- stem cell
- tissues
- conducting
- Prior art date
Links
- 210000000130 stem cell Anatomy 0.000 title abstract 8
- 238000000034 method Methods 0.000 title abstract 6
- 238000003556 assay Methods 0.000 title abstract 4
- 238000002955 isolation Methods 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 241000699666 Mus <mouse, genus> Species 0.000 abstract 3
- 239000002458 cell surface marker Substances 0.000 abstract 3
- 210000004027 cell Anatomy 0.000 abstract 2
- 210000001519 tissue Anatomy 0.000 abstract 2
- 241000283073 Equus caballus Species 0.000 abstract 1
- 101000692109 Homo sapiens Syndecan-2 Proteins 0.000 abstract 1
- 241000283973 Oryctolagus cuniculus Species 0.000 abstract 1
- 241000700159 Rattus Species 0.000 abstract 1
- 241000282898 Sus scrofa Species 0.000 abstract 1
- 102100026087 Syndecan-2 Human genes 0.000 abstract 1
- 210000001185 bone marrow Anatomy 0.000 abstract 1
- 241000894007 species Species 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/37—Digestive system
- A61K35/407—Liver; Hepatocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0607—Non-embryonic pluripotent stem cells, e.g. MASC
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0669—Bone marrow stromal cells; Whole bone marrow
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1202319.8A GB201202319D0 (en) | 2012-02-10 | 2012-02-10 | Stromal stem cells |
| PCT/EP2013/052692 WO2013117761A1 (en) | 2012-02-10 | 2013-02-11 | Stromal stem cells |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112014019277A2 BR112014019277A2 (enExample) | 2017-06-20 |
| BR112014019277A8 true BR112014019277A8 (pt) | 2017-07-11 |
Family
ID=45929927
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112014019277A BR112014019277A8 (pt) | 2012-02-10 | 2013-02-11 | Populações de células-tronco estromais, tecidos, métodos de isolamento de células-tronco estromais, método de obtenção de tecido, ensaio e método para condução de ensaio e composição farmacêutica |
Country Status (22)
| Country | Link |
|---|---|
| US (10) | US11230700B2 (enExample) |
| EP (4) | EP3492584B1 (enExample) |
| JP (1) | JP5829765B2 (enExample) |
| KR (1) | KR102124837B1 (enExample) |
| CN (1) | CN104302763B (enExample) |
| AU (1) | AU2013217870B2 (enExample) |
| BR (1) | BR112014019277A8 (enExample) |
| CA (1) | CA2863821C (enExample) |
| CY (1) | CY1116365T1 (enExample) |
| DK (1) | DK2758523T3 (enExample) |
| ES (3) | ES2959833T3 (enExample) |
| GB (1) | GB201202319D0 (enExample) |
| HR (1) | HRP20150594T1 (enExample) |
| HU (1) | HUE026480T2 (enExample) |
| IN (1) | IN2014KN01777A (enExample) |
| PL (1) | PL2758523T3 (enExample) |
| PT (1) | PT2758523E (enExample) |
| RS (1) | RS54073B1 (enExample) |
| RU (1) | RU2636551C2 (enExample) |
| SI (1) | SI2758523T1 (enExample) |
| SM (1) | SMT201500147B (enExample) |
| WO (1) | WO2013117761A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201202319D0 (en) | 2012-02-10 | 2012-03-28 | Orbsen Therapeutics Ltd | Stromal stem cells |
| US10251934B2 (en) | 2013-04-16 | 2019-04-09 | Orbsen Therapeutics Limited | Syndecan-2 compositions and methods of use |
| US20170044497A1 (en) | 2014-02-12 | 2017-02-16 | National University Of Ireland, Galway | Selection and use of stem cells |
| KR101690872B1 (ko) | 2014-08-19 | 2016-12-29 | 이화여자대학교 산학협력단 | 편도 유래 중간엽 줄기세포로부터 인슐린 분비 세포의 분화 방법 |
| US9716660B2 (en) * | 2014-12-11 | 2017-07-25 | Intel Corporation | Hierarchical enforcement of service flow quotas |
| KR101686315B1 (ko) | 2015-01-09 | 2016-12-13 | 이화여자대학교 산학협력단 | 편도 유래 중간엽 줄기세포로부터 슈반 세포의 분화 방법 |
| WO2016123163A2 (en) | 2015-01-27 | 2016-08-04 | Kardiatonos, Inc. | Biomarkers of vascular disease |
| JP6920207B2 (ja) | 2015-03-20 | 2021-08-18 | オルブセン セラピューティクス リミテッド | シンデカン−２のモジュレーターとその使用 |
| US11918687B2 (en) | 2016-01-15 | 2024-03-05 | Orbsen Therapeutics Limited | SDC-2 exosome compositions and methods of isolation and use |
| CN106177918A (zh) * | 2016-09-30 | 2016-12-07 | 广州赛莱拉干细胞科技股份有限公司 | 一种间充质干细胞注射液及其制备方法和应用 |
| WO2018220442A2 (en) * | 2017-05-30 | 2018-12-06 | Orbsen Therapeutics Limited | Stromal stem cell therapeutics and methods of use |
| EP3652305A2 (en) * | 2017-07-14 | 2020-05-20 | Orbsen Therapeutics Limited | Cd39 stromal stem cells methods of isolation and use |
| CN114761036B (zh) | 2019-09-23 | 2025-09-30 | 宾夕法尼亚大学董事会 | 与小鼠和人成纤维细胞激活蛋白(fap)交叉反应的抗犬成纤维细胞激活蛋白单克隆抗体 |
| AU2020353000A1 (en) * | 2019-09-23 | 2022-04-07 | The Trustees Of The University Of Pennsylvania | Disrupting tumor tissues by targeting fibroblast activation protein (FAP) |
| WO2022179518A1 (en) * | 2021-02-25 | 2022-09-01 | Rosas Ivan O | Anti-fibrotic peptides and uses thereof |
| CN116334214A (zh) * | 2023-04-04 | 2023-06-27 | 暨南大学附属第一医院（广州华侨医院） | 一种用于急性心肌梗死和稳定性心绞痛鉴别的生物标志物的ceRNA调控网络及其应用 |
| IT202300007497A1 (it) * | 2023-04-18 | 2024-10-18 | Comecer Spa | Isolatore per colture cellulari derivate da un tessuto perinatale e metodo di isolamento di almeno una tipologia di cellule da un tessuto perinatale |
Family Cites Families (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1012403A (en) | 1911-01-23 | 1911-12-19 | Thomas W Mcneill | Smoke-indicator. |
| US5486599A (en) | 1989-03-29 | 1996-01-23 | The Board Of Trustees Of The Leland Stanford Junior University | Construction and use of synthetic constructs encoding syndecan |
| US5486359A (en) * | 1990-11-16 | 1996-01-23 | Osiris Therapeutics, Inc. | Human mesenchymal stem cells |
| US5726058A (en) | 1992-12-01 | 1998-03-10 | Jalkanen; Markku | Syndecan stimulation of cellular differentiation |
| WO1997034605A1 (en) | 1996-03-21 | 1997-09-25 | Mayo Foundation For Medical Education And Research | Use of nicotine to treat liver disease |
| ATE286118T1 (de) * | 1998-03-13 | 2005-01-15 | Osiris Therapeutics Inc | Anwendungen für humane nicht autologe, mesenchymale stammzellen |
| DE69936720T2 (de) | 1998-05-29 | 2008-04-30 | Osiris Therapeutics, Inc. | Menschliche cd45+ und/oder fibroblasten+ mesenchymale stammzellen |
| AU5723601A (en) | 2000-04-25 | 2001-11-07 | Osiris Therapeutics Inc | Joint repair using mesenchymal stem cells |
| US7442390B2 (en) * | 2000-06-05 | 2008-10-28 | University Of South Florida | Method for enhancing engraftment of cells using mesenchymal progenitor cells |
| WO2002087609A1 (en) | 2001-05-01 | 2002-11-07 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Identification of a cell surface receptor for papillomaviruses |
| CA2468292A1 (en) * | 2001-11-26 | 2003-06-05 | Advanced Cell Technology, Inc. | Methods for making and using reprogrammed human somatic cell nuclei and autologous and isogenic human stem cells |
| AU2003214857A1 (en) | 2002-01-18 | 2003-09-02 | Regents Of The University Of Minnesota | Syndecans and angiogenesis |
| CA2490261A1 (en) | 2002-06-27 | 2004-01-08 | The University Of Queensland | Differentiation modulating agents and uses therefor |
| AU2003296338A1 (en) * | 2002-12-05 | 2004-06-30 | Case Western Reserve University | Cell-based therapies for ischemia |
| JP2007531707A (ja) | 2003-10-15 | 2007-11-08 | ピーディーエル バイオファーマ， インコーポレイテッド | ＩＧの重鎖定常領域の位置２５０、３１４および／または４２８の変異誘発によるＦｃ融合タンパク質血清半減期の改変 |
| EP2824175B2 (en) | 2004-03-22 | 2020-10-28 | Mesoblast International Sàrl | Mesenchymal stem cells and uses therefor |
| JP5668208B2 (ja) * | 2004-08-16 | 2015-02-12 | セルリサーチ コーポレイション ピーティイー リミテッド | 臍帯羊膜からの幹／前駆細胞の単離 |
| US20060045872A1 (en) * | 2004-08-25 | 2006-03-02 | Universidad Autonoma De Madrid Ciudad Universitaria de Cantoblanco | Use of adipose tissue-derived stromal stem cells in treating fistula |
| US11268149B2 (en) | 2004-12-08 | 2022-03-08 | Cedars-Sinai Medical Center | Diagnosis and treatment of inflammatory bowel disease |
| EP1795588A1 (en) | 2005-12-07 | 2007-06-13 | Cellerix, S.L. | Use of adipose tissue derived mesenchymal stem cells for the treatment of graft versus host disease |
| JP5283219B2 (ja) | 2006-04-20 | 2013-09-04 | 学校法人自治医科大学 | ベクター産生型腫瘍標的細胞 |
| US20070264239A1 (en) | 2006-05-10 | 2007-11-15 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Isolation of pericytes |
| WO2008085229A2 (en) | 2006-11-15 | 2008-07-17 | Arteriocyte Inc. | Cell-based therapies for treating liver disease |
| US20080131415A1 (en) | 2006-11-30 | 2008-06-05 | Riddell Stanley R | Adoptive transfer of cd8 + t cell clones derived from central memory cells |
| KR100883565B1 (ko) | 2007-02-14 | 2009-02-13 | (주)프로스테믹스 | 지방 줄기세포의 조직 재생 능력을 최적화한 조건 배지를 함유한 조직 재생용 주사제 첨가제 |
| US20100111914A1 (en) | 2007-05-21 | 2010-05-06 | Yuanyuan Zhang | Stem cells from urine and methods for using the same |
| KR20080103637A (ko) * | 2007-05-25 | 2008-11-28 | 주식회사 알앤엘바이오 | 지방유래 줄기세포를 함유하는 사지말단부 허혈성 질환의세포치료용 조성물 |
| EP2676678A1 (en) | 2007-07-17 | 2013-12-25 | The General Hospital Corporation | Methods to identify and enrich populations of ovarian cancer stem cells and somatic stem cells and uses thereof |
| US20100247577A1 (en) | 2007-10-17 | 2010-09-30 | Txcell | Tr1 cells, mesenchymal stem cells and uses thereof |
| US20090275608A1 (en) * | 2008-02-04 | 2009-11-05 | Bipar Sciences, Inc. | Methods of diagnosing and treating parp-mediated diseases |
| US20090220588A1 (en) | 2008-02-21 | 2009-09-03 | Massachusetts Institute Of Technology | Simultaneous Delivery of Receptors and/or Co-Receptors for Growth Factor Stability and Activity |
| KR20100106744A (ko) | 2009-03-24 | 2010-10-04 | 이화여자대학교 산학협력단 | 이동성 피부세포질환 또는 멜라닌 합성관련 질환 예방 또는치료용 조성물 |
| EP2419113B1 (en) | 2009-04-13 | 2017-05-10 | Apceth GmbH & Co. KG | Engineered mesenchymal stem cells and method of using same to treat tumors |
| KR101301262B1 (ko) | 2009-10-23 | 2013-08-27 | 가톨릭대학교 산학협력단 | ＴＧＦβ를 코딩하는 뉴클레오티드 서열이 도입된 간엽줄기세포 및 그의 용도 |
| KR101622650B1 (ko) | 2009-12-31 | 2016-06-01 | 엘지디스플레이 주식회사 | 액정 전계 렌즈 및 이를 이용한 입체 표시 장치 |
| US9394521B2 (en) | 2010-03-10 | 2016-07-19 | Two Cells Co., Ltd. | Cell preparation containing mesenchymal stem cells, and method for producing same |
| US20130189275A1 (en) | 2010-06-03 | 2013-07-25 | University Of Rochester | Compositions and methods for inhibition of or treatment of dengue virus infection |
| ES2667532T3 (es) | 2010-06-18 | 2018-05-11 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Neogénesis del folículo piloso |
| KR101309910B1 (ko) | 2010-08-06 | 2013-09-17 | 이화여자대학교 산학협력단 | 대장암 진단 및 치료제로서의 신데칸-2 펩티드 단편 |
| KR101317507B1 (ko) | 2010-08-30 | 2013-10-15 | 가톨릭대학교 산학협력단 | 레바미피드를 유효성분으로 포함하는 암 또는 면역질환의 예방 또는 치료용 조성물 |
| WO2012088225A2 (en) * | 2010-12-22 | 2012-06-28 | Tulane University | Method for identifcation and culture of multipotent mesenchymal stem cells with high proliferation potential |
| KR20120095022A (ko) | 2011-02-18 | 2012-08-28 | 가톨릭대학교 산학협력단 | 간엽줄기세포 및 면역조절 ｔ 세포를 유효성분으로 포함하는 이식편대숙주질환 예방 또는 치료용 세포치료제 조성물 |
| ES2629502T3 (es) | 2011-03-11 | 2017-08-10 | Children's Medical Center Corporation | Métodos y composiciones relacionados con exosomas de células madre mesenquimales |
| KR101145406B1 (ko) * | 2011-07-06 | 2012-05-15 | (주)지노믹트리 | 장암 진단을 위한 장암 특이적 메틸화 마커 유전자의 메틸화 검출방법 |
| GB201202319D0 (en) | 2012-02-10 | 2012-03-28 | Orbsen Therapeutics Ltd | Stromal stem cells |
| US20150030615A1 (en) * | 2012-03-09 | 2015-01-29 | Verastem, Inc. | Biomarkers for cancer stem cells and related methods of use |
| WO2013172793A1 (en) | 2012-05-18 | 2013-11-21 | Agency For Science, Technology & Research | Umbilical cord mesenchymal stem cell exosomes |
| JP6542197B2 (ja) | 2013-04-12 | 2019-07-10 | エヴォックス・セラピューティクス・リミテッド | 治療的送達小胞 |
| US10251934B2 (en) | 2013-04-16 | 2019-04-09 | Orbsen Therapeutics Limited | Syndecan-2 compositions and methods of use |
| WO2015038075A1 (en) | 2013-09-16 | 2015-03-19 | Agency For Science, Technology And Research | Method |
| EP3091991B1 (en) | 2013-12-13 | 2019-11-06 | IsletOne AB | Immunomodulatory compositions |
| EP3182984B1 (en) | 2014-08-18 | 2019-10-30 | Apceth GmbH & Co. KG | Genetically modified mesenchymal stem cells expressing an immune response-stimulating cytokine to attract and/or activate immune cells |
| MX2017004742A (es) | 2014-10-20 | 2017-07-20 | Nestec Sa | Métodos para la predicción de niveles de farmacos anti-tnf alfa y formación de autoanticuerpos. |
| GB201418562D0 (en) | 2014-10-20 | 2014-12-03 | Univ London Queen Mary | Peptides |
| JP6920207B2 (ja) | 2015-03-20 | 2021-08-18 | オルブセン セラピューティクス リミテッド | シンデカン−２のモジュレーターとその使用 |
| US11918687B2 (en) | 2016-01-15 | 2024-03-05 | Orbsen Therapeutics Limited | SDC-2 exosome compositions and methods of isolation and use |
| MX376974B (es) | 2016-02-19 | 2025-03-07 | Phoenix Molecular Designs | Derivados de carboxamida útiles como inhibidores de rsk. |
| WO2018220442A2 (en) | 2017-05-30 | 2018-12-06 | Orbsen Therapeutics Limited | Stromal stem cell therapeutics and methods of use |
| EP3652305A2 (en) | 2017-07-14 | 2020-05-20 | Orbsen Therapeutics Limited | Cd39 stromal stem cells methods of isolation and use |
| CN112703201A (zh) | 2018-07-05 | 2021-04-23 | 诺沃班德畜牧业治疗公司 | 针对家禽致病原的抗体和其用途 |
| EP4556072A3 (en) | 2019-08-23 | 2025-06-11 | Orbsen Therapeutics Limited | Compositions for monocyte and macrophage polarization and methods of use |
-
2012
- 2012-02-10 GB GBGB1202319.8A patent/GB201202319D0/en not_active Ceased
-
2013
- 2013-02-11 KR KR1020147025152A patent/KR102124837B1/ko active Active
- 2013-02-11 EP EP18190005.1A patent/EP3492584B1/en active Active
- 2013-02-11 JP JP2014556093A patent/JP5829765B2/ja active Active
- 2013-02-11 EP EP23176834.2A patent/EP4257203A3/en active Pending
- 2013-02-11 ES ES18190005T patent/ES2959833T3/es active Active
- 2013-02-11 HR HRP20150594TT patent/HRP20150594T1/hr unknown
- 2013-02-11 PT PT137072955T patent/PT2758523E/pt unknown
- 2013-02-11 BR BR112014019277A patent/BR112014019277A8/pt not_active Application Discontinuation
- 2013-02-11 DK DK13707295.5T patent/DK2758523T3/da active
- 2013-02-11 EP EP13707295.5A patent/EP2758523B1/en active Active
- 2013-02-11 HU HUE13707295A patent/HUE026480T2/en unknown
- 2013-02-11 US US14/377,597 patent/US11230700B2/en active Active
- 2013-02-11 RS RS20150392A patent/RS54073B1/sr unknown
- 2013-02-11 ES ES13707295.5T patent/ES2539186T3/es active Active
- 2013-02-11 PL PL13707295T patent/PL2758523T3/pl unknown
- 2013-02-11 CN CN201380019351.0A patent/CN104302763B/zh active Active
- 2013-02-11 CA CA2863821A patent/CA2863821C/en active Active
- 2013-02-11 WO PCT/EP2013/052692 patent/WO2013117761A1/en not_active Ceased
- 2013-02-11 ES ES15158384T patent/ES2697780T3/es active Active
- 2013-02-11 SI SI201330036T patent/SI2758523T1/sl unknown
- 2013-02-11 EP EP15158384.6A patent/EP2902482B1/en active Active
- 2013-02-11 AU AU2013217870A patent/AU2013217870B2/en active Active
- 2013-02-11 RU RU2014136711A patent/RU2636551C2/ru active
-
2014
- 2014-08-22 IN IN1777KON2014 patent/IN2014KN01777A/en unknown
-
2015
- 2015-06-08 CY CY20151100502T patent/CY1116365T1/el unknown
- 2015-06-25 SM SM201500147T patent/SMT201500147B/xx unknown
-
2016
- 2016-04-01 US US15/089,435 patent/US10907131B2/en active Active
-
2018
- 2018-06-14 US US16/009,048 patent/US11142747B2/en active Active
-
2019
- 2019-09-05 US US16/562,206 patent/US10920197B2/en active Active
-
2021
- 2021-09-09 US US17/470,492 patent/US11926848B2/en active Active
- 2021-12-01 US US17/540,067 patent/US11434471B2/en active Active
-
2023
- 2023-06-05 US US18/329,469 patent/US11952590B2/en active Active
- 2023-06-05 US US18/329,435 patent/US11884936B2/en active Active
- 2023-06-05 US US18/329,455 patent/US11952589B2/en active Active
-
2024
- 2024-03-07 US US18/599,002 patent/US20240209319A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112014019277A8 (pt) | Populações de células-tronco estromais, tecidos, métodos de isolamento de células-tronco estromais, método de obtenção de tecido, ensaio e método para condução de ensaio e composição farmacêutica | |
| BR112015023262A2 (pt) | anticorpo isolado, ácido nucleico isolado, célula hospedeira, método para produzir um anticorpo, imunoconjugado, formulação farmacêutica e usos do anticorpo | |
| BR112015017548A8 (pt) | construção de anticorpo multiespecífico isolado, sequência de ácido nucléico, vetor, célula hospedeira, processo para a produção da construção de anticorpo, composição farmaceutica, uso da construção de anticorpo e kit | |
| BR112015017307A2 (pt) | composições de espécies com baixa acidez e métodos para produção e uso das mesmas | |
| BR112019000512A2 (pt) | anticorpo, ácido nucleico, vetor de expressão, célula hospedeira, composição, métodos de tratamento de uma doença, para produzir um anticorpo biespecífico e para detectar se a reticulação entre as células que expressam cd40 e cd137 ocorre em uma amostra, uso de um anticorpo multiespecífico, e, kit | |
| BR112015014833B8 (pt) | Anticorpo isolado ou fragmento de ligação, ácido nucleico, método in vitro, kit e composição de anticorpo | |
| BR112012009289A8 (pt) | Método para purificar um anticorpo anti-il-13 a partir de uma mistura de amostra que compreende um anticorpo anti-il-13 e pelo menos uma proteína de célula hospedeira (hcp) | |
| BR112013004012A2 (pt) | anticorpos para o receptor de fator de crescimento epidérmico 3 (her3). | |
| BRPI0909044B8 (pt) | anticorpo que se liga especificamente ao csf-1r humano,composição farmacêutica e uso dos mesmos | |
| BR112012032991A2 (pt) | camundongo expressando uma imunoglobulina de cadeia leve híbrida. | |
| BR112014008694A2 (pt) | moléculas de ácido nucleico policistrônico recombinante | |
| BR112013033488A2 (pt) | marcadores biológicos de micro-rna indicativo da doença de alzheimer | |
| BR112012023010A2 (pt) | "anticorpo ou fragmento de ligação a antígeno do mesmo que se liga especificamente a cd37, imunoconjugado compreendendo os mesmos, uso dos referidos anticorpo, fragmento e imunoconjugado, composição compreendendo os mesmos, kit, célula isolada, bem como método in vitro para inibir o crescimento de uma célula que expressa cd37" | |
| BR112012024710A8 (pt) | moléculas que se ligam ao antígeno, seus processos de produção, bem como composição farmacêutica que as compreendem | |
| UY32501A (es) | Anticuerpo antagonista específico para el heterodímero alfa4-beta7 | |
| BR112012001984B8 (pt) | anticorpos humanos com alta afinidade para angiopoietina-2 humana, uso dos mesmos e composição farmacêutica | |
| BR112015026716A2 (pt) | Molécula de ligação de antígeno específica do icosl; proteína de fusão; ácido nucleico que codifica uma molécula de ligação de antígeno específica do icosl; construto de ácido nucleico; célula hospedeira; processo para produção de uma molécula de ligação de antígeno específica do icosl; composição farmacêutica de uma molécula de ligação de antígeno específica do icosl; uso de uma molécula de ligação de antígeno específica do icosl; método de tratamento de uma doença em um paciente em necessidade de tratamento; método de ensaio de um analito alvo em uma amostra; método de formação de imagem de um local da doença em um indivíduo; e método de diagnóstico de uma doença ou condição médica em um indivíduo | |
| CL2007002412A1 (es) | Anticuerpo especifico para el dominio extracelular del receptor de prolactina (prlr); molecula de acido nucleico que lo codifica; vector de expresion y celula huesped que la comprenden; metodo de produccion; composicion farmaceutica que comprende al | |
| BR112017004899A2 (pt) | detecção de proteínas mal dobradas | |
| BR112016014913A8 (pt) | anticorpo, ou um fragmento de ligação ao antígeno do mesmo, conjugado, ácido nucléico, vetor, célula hospedeira, composição farmacêutica, método de preparo de uma cadeia leve de um anticorpo ou fragmento de ligação ao antígeno e método de preparo de um conjugado | |
| BR112016009460A8 (pt) | método para detectar a presença de anticorpos neutralizantes, e, kit | |
| AR088244A1 (es) | oxMIF COMO MARCADOR DE DIAGNOSTICO | |
| BR112014003272A2 (pt) | método e kit para o sucesso da previsão de fertilização in vitro | |
| BR112017022205A2 (pt) | anticorpo anti-vegfr2 humano para terapia de câncer antiangiogênica e objetivada | |
| BR112018000257A2 (pt) | célula hospedeira, método para produzir um haa, uso de uma célula hospedeira, método para produzir uma célula hospedeira, célula, preparação de haa, método para produzir uma composição de ácido graxo e composição de ácido graxo |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |